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Pharmacogenetics is moving rapidly to assemble a
large set of polymorphisms that define the influence
of genetic diversity on human drug response. Sci-
entific and technological advances of the last 10
years have led to new approaches to the discovery
of genetic drug susceptibility loci, the development
of high-tech analytical strategies for drug suscepti-
bility profiling, and a flood of new gene discover-
ies in the area of receptors and receptor polymor-
phisms. Extension and refinement of our
knowledge of human genetic diversity is essential
to the use of drugs in more of an individualized
manner and to the discovery of better therapies,
but knowledge of the functional consequences of
this diversity, the next great challenge in pharma-
cogenetics, provides the best chance to profit from
this diversity. Environ. Mol. Mutagen. 37:
179–184, 2001. © 2001 Wiley-Liss, Inc.
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INTRODUCTION
Physicians rely on drugs as therapeutic agents because of
the characteristic, reproducible effects they exert on per-
sons. Unfortunately, for those who fail to respond as ex-
pected, or suffer toxicity from these agents, the effects are
all too apparent. Researchers discovered decades ago that
genetics affects person-to-person variation in responses to
drugs and other xenobiotics. Pharmacogenetics, a field pri-
marily concerned with understanding how genetic diversity
within populations influences drug effectivenes and toxic-
ity, provides the experimental framework for dissecting the
causes of this variation. Knowing the intrinsic variation in
the human genetic anatomy and its functional consequences
wil l permit genetic profiles for individuals to beconstructed
that wil l enable physicians to identify persons likely to be
susceptible to unexpected drug responses. It is hoped and
expected that drug susceptibility profiles can be used to
select drugs better fitted to safe, effective therapy and to
design better therapies. As aconsequence, pharmacogenet-
ics isexperiencing aperiod of rapid growth and redefinition.
This communication describes the present state of pharma-
cogenetics and highlights some of the challenges of the near
future that face pharmacogenetics. Because pharmacogenetics
ismistakenly perceived in somecirclesasan outgrowth of the
biological revolution accompanying recombinant DNA tech-
nology, we begin with abrief history of the field.
ORIGIN AND DEVELOPMENT OF
PHARMACOGENETICS
Pharmacogenetics has a rich history with several roots.
Up to about 1990, the emergence and growth of the field
fallsneatly into threeperiods, thefirst of which began about
150 years ago, the second began about 1910, and the third
about 1950.
Around 1850 and extending to about 1910, physiological
chemists, mainly in European laboratories, found that hu-
mans were capable of metabolizing most drugs and exoge-
nous chemicals they ingested. In the 1860s, Mendel discov-
ered the fundamental laws of heredity, but his findings were
unappreciated until their rediscovery by othersaround 1900.
And in the 1870s, Ehrlich and Langley inferred the exis-
tence of drug receptor molecules to account for the speci-
ficity of drug action on tissues. Conceptually, the origin of
pharmacogenetics is closely tied to these three discoveries.
During the second period from 1910 to about 1950, the
importance of these discoveries began to emerge when
Archibald Garrod and William Bateson in England and
Lucien Cuenot in Francesuggested that thegenetic material
played a crucial part in directing the chemical transforma-
tions described by physiological chemists. Garrod was first
to realizethat enzymescould act asdetoxifiersof exogenous
substances; he believed that the poisonous effects of drugs
experienced by certain persons was likely the result of a
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failure of their enzymes to detoxify those substances. He
stressed these ideas in writings and teachings until his death
in the 1930s as evidence gradually accumulated for the
importance of chemical individuality of humans. During the
1920s and 1930s, the traits of “odor blindness” and “taste
blindness” were recognized, and detailed study of taste
blindness revealed the high specificity, inheritance, and
ethnic variability that characterize human responsiveness to
chemicals. Another decade would pass, however, before we
learned from studies of sickle cell anemia and sickle cell
trait (1948–1950) that these disorders were caused by an
aberrant form of protein (hemoglobin S), and that the re-
sponses of persons to the environment reflected the proper-
ties of proteins they synthesize [reviewed in Weber, 1997].
The third period begins around 1950 and extends until
about 1990. During this period the importance of genetic
variation to the safe use of drugs was firmly established.
Early in this period, several breakthroughs occurred in short
order, prompting biologists to take a more genetic approach
to their research. Discovery of the double helix of DNA
defined the molecular basis of heredity, human chromo-
somes were visualized and enumerated, and protein poly-
morphism was recognized as a phenomenon of major bio-
logical significance. New techniques for separating drugs
and their metabolites and a desire to get at the causes of
unexpected drug responses enabled pharmacologists with a
biochemical bent to describe heritable patterns of metabo-
lism and response for several drugs (1953–1956).
About 100 monogenic, polymorphic traits of pharmaco-
genetic interest were identified by about 1990. The lion’s
share of these were found to be attributed to polymorphic
isoforms of the drug-metabolizing enzymes, affirming again
and again Garrod’s idea of enzymes as detoxifiers of envi-
ronmental chemicals. Rigorous pharmacological and ge-
netic characterization of these traits were chiefly responsible
for shaping the initial development of the field and estab-
lishing pharmacogenetics as an experimental science.
TRANSITION TO THE FUTURE, 1990 –2000
The advent of molecular genetics during the 1980s radi-
cally altered the way of doing modern biology. Cloning,
sequencing, and site-directed mutagenesis became the norm
for studying the organization and composition of genes.
Widespread application of recombinant DNA techniques
quickened the pace of investigation and enabled the iden-
tity, chromosomal location, and characteristics of genes for
virtually every known pharmacogenetic trait that had been
determined. To keep everyone abreast of a rapidly expand-
ing and intimidating body of evidence and of new directions
in research, a plethora of educational programs, workshops,
and conferences were produced to create awareness of these
advances. Moreover, efforts to find new ways to catalog the
new knowledge about genes, compare variations in their
expression, study their interactions, and identify their func-
tions have encouraged scientists in academia and industry to
form partnerships for the betterment of testing pharmaco-
g netic initiatives.
Novel Approaches to the Discovery of Drug
Susceptibility Loci
One of the first changes to occur concerned the way to
seek genes that might alter person-to-person susceptibility
to drugs. Traditionally, pharmacogeneticists had relied on
patterns of inheritance of phenotypic criteria to identify
genetic factors implicated in an altered drug response. The
susceptible phenotype usually had physiologic, biochemi-
cal, pharmacologic, or toxicologic features that could lead
to inferences about the identity of the protein and even the
gene and allelic variants responsible for the phenotype. For
instance, in the 1950s, to explain the susceptibility of per-
sons to succinylcholine sensitivity, Kalow inferred the ex-
istence of a genetic variant of serum cholinesterase from the
presence of a serum cholinesterase with unusual resistance
to inhibition by dibucaine. About the same time, to explain
the susceptibility of persons to isoniazid-induced nerve
damage, the existence of a genetic variant of acetyltrans-
ferase was inferred from low levels of acetylated isoniazid
metabolites in the urine of patients administered the drug
[see references in Weber, 1987, Chapters 2 and 3].
With the advent of recombinant DNA technology, how-
ever, the genes for serum cholinesterase, acetyltransferase,
as well as for many other monogenic traits were cloned and
sequenced, and the existence of variant genes demonstrated.
Thus the connection could now be directly established be-
tween a susceptible phenotype and its genotype that here-
tofore could only be inferred. That is, by starting with the
gene sequence and proceeding through expression of the
protein, the susceptible biochemical or physiological phe-
notype was determined.
Nowadays, because a gene sequence and its chromo-
somal location can be determined relatively easily, the anat-
omy of a gene and its position may be known before its
function or the phenotype it determines. Hence, use of the
combined information on function and position has become
increasingly common as a means of gene identification
[Ballabio, 1993].
Invention of Techniques to Facilitate Drug Discovery
A number of techniques have been invented for identify-
i g and scoring polymorphisms [see Box 1, Schafer and
Hawkins, 1998]. Where the primary focus for research and
diagnosis has been on simple, high-throughput analysis,
techniques such as the DNA microarray and Invader tech-
nologies are outstanding.
Increasing demand for analytical techniques that could
accommodate a high density of information to sequence,
map, and identify human genes led to the development of
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DNA microarrays. DNA microarrays, like all other DNA
hybridization analytical technologies, are modifications of
the “Southern blot” devised by Edwin Southern in 1975
[Weber and Cronin, 2000]. The Southern blot uses the
specificity of DNA restriction endonucleases combined with
gel electrophoresis to separate and identify DNA fragments.
Southern’s method quickly evolved into several other tech-
niques. First, the Northern blot (1977) and then DNA fin-
gerprinting (1985) were devised. In 1989, “dot” blots and
“slot” blots, which used test samples of DNA as the immo-
bilized species for analysis of DNA fragments, were de-
vised. They were faster and could accommodate smaller
DNA samples than previous techniques. Later, polymerase
chain reaction (PCR) permitted the development of the
“reverse dot blot,” in which DNA probes, instead of DNA
test samples, became the immobilized species (1991–1994).
In 1994, Southern, again at the forefront of advances, first
described the in situ synthesis of an oligonucleotide array on
solid supports [reviewed in Weber and Cronin, 2000]. Ap-
plication of his method and its modifications led to microar-
rays, which consist of segments of complementary DNA
(cDNA) or of expressed sequence tags immobilized on a
solid support.
Despite remarkable innovation and rapid technical im-
provement since then, improved fabrication, reduced costs,
and enhanced robustness and reliability must yet be
achieved before microarrays reach their full potential as
analytical tools. There are also significant challenges in
storage and handling of vast amounts of information that
microarrays have created. New concepts are also needed to
relate large complex sets of genetic data to clinical pheno-
types. Hence, predictive testing is currently available for
only a very few, if any, applications based on DNA mi-
croarray profiling.
Microarray analysis allows all of the genes in a system to
be monitored at once instead of one gene at a time, thus
enabling the collection of large amounts of genetic data
from comparatively few experiments. Currently, microarray
applications span many aspects of molecular biological
investigation by helping to diagnose diseases, illuminate
developmental and physiological pathways, measure and
compare perturbations in gene activities and patterns of
gene expression in cancer and other pathological states, and
screen drug candidates for new therapies.
With respect to pharmacogenetics, microarrays are used
mainly as research tools to learn the most effective ways of
gathering information for the construction of genetic pro-
files of susceptibility to unexpected responses to drugs and
other xenobiotics.
The Invader system of techniques that has been devel-
oped more recently provides another analytical method for
investigating alterations of the human genome. The Invader
system finds its origin in the properties of the cleavase
enzymes derived from structure-specific endonucleases that
are essential for DNA replication, recombination, and repair
[Kwiatkowski et al., 1999 and references therein]. Invader
techniques can use genomic DNA directly from small blood
volumes, or cell lysates, for genotyping and they can dis-
criminate mutant from wild-type genotypes in mixed pop-
ulations at very low ratios (1/1000 or lower) of mutant/wild
ype. In the case of gene expression analysis, the technique
can quantitate closely related messages within the same
sample. Additionally, this technology is adaptable for use in
large-scale analysis of single-nucleotide polymorphisms
(SNPs) that use high-throughput screening methods of de-
tection such as the fluorescence-based (FRET) system and
matrix-assisted laser desorption/ionization time of flight
(MALDI/TOF) mass spectrometry. Applications of the In-
vader system to factor V Leiden, factor II (prothrombin),
cystic fibrosis, and apolipoprotein E, and to measurement of
mRNA levels of ubiquitin demonstrate its validity for mu-
tation detection, SNP profiling, and gene expression analy-
sis. The Invader technology is quite promising as a new tool
for research and clinical application in pharmacogenetics.
The Flood of New Gene Discoveries
Among all the genes whose structure and function have
been elucidated during the last decade, the genes for recep-
tors and receptor polymorphisms stand out. Cell surface
r ceptors are the primary focus of the following discussion
not only because they account for the response of cells to
most drugs, biogenic amines, protein and polypeptide hor-
mones, autocoids, and neurotransmitters, but also because
susceptibility profiles that are associated with several pro-
t typic polymorphisms of these receptors have been iden-
tified [Weber, 2001].
The association of polymorphic variants of ion channels
to cardiovascular disease yields several important examples.
For K1 channels [Curran, 1998], genetic and physiologic
studies indicate that mutations in four loci are implicated in
susceptibility to the long QT (LQT) syndrome (LQT 1, 2, 5,
and6). These variants are associated with cardiac arrhyth-
mias. Homozygosity of theKVLQT1 variant, identified in
1991, causes the Jervell Lange–Nielsen syndrome (LQT
plus deafness), whereas heterozygosity causes the Romano–
Ward syndrome (LQT only), the most common inherited
form of LQTs. Mutation of the Na1 channel (SCN5A5
LQT3) is also associated with cardiac arrhythmias. Knowl-
ge of the LQT genotype that results in a specific clinical
phenotype may provide a basis for gene-specific drug ther-
apy. For example, potassium supplementation or potassium
channel openers are useful in treating patients with potas-
sium channel defects, whereas sodium channel blockers
(e.g., mexilitene) may be more effective in treating patients
with LQT3.
The b2-adrenergic receptor, a prototypic example of G-
protein receptors [Lefkowitz, 2000], has been targeted for
investigation of susceptibility to asthma since the beta-
adrenergic receptor theory of atopy was proposed 30 years
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ago. The receptor was cloned, sequenced, and mapped in
1987. Initial molecular studies revealed a total of nine
naturally occurring single-nucleotide polymorphisms
(SNPs). Three SNPs resulted in changes in amino acids 16
and 27 of the receptor, which altered its abundance and
function, but a more recent study identifies a total of 13
SNPs organized into 12 haplotypes [Drysdale et al., 2000].
Studies in Caucasian, African-American, Asian, and His-
panic-Latino populations revealed more than 20-fold differ-
ences among the frequencies of the four major haplotypes in
these populations. The responses to bronchodilator therapy
with albuterol of individuals with the five most common
b2-adrenergic receptor haplotypes were determined in vivo
by haplotype pair; the mean responses varied by more than
twofold. Although the mean responses were significantly
related to haplotype pair, they were not related to individual
SNPs. This study is among the first to indicate that interac-
tions between SNPs within a haplotype can affect biologic
and therapeutic phenotype, and may have prognostic signif-
icance in assessing individual variation in drug response.
PROFITING FROM HUMAN GENETIC DIVERSITY
The use of genetic information to predict human respon-
siveness to pharmaceutical agents and other exogenous
chemicals is the foremost purpose of pharmacogenetics.
Physicians know that a patient with a genetic drug suscep-
tibility is no less treatable than many other patients they
manage by restricting access to, or by replacing and/or
removing, the offending substance from the environment. It
follows that, if treatment is guided by profiles for suscepti-
bility of individuals to specific drugs, the occurrence of
unexpected responses among genetically susceptible per-
sons might be averted.
Pharmacogenetics is well positioned to synthesize such
profiles by virtue of having an extensive base of reliable
data about monogenic traits attributable to drug-metaboliz-
ing enzyme polymorphisms and numerous other polymor-
phisms. Indeed, these traits are remarkable prognosticators
of therapeutic failure of, or unexpected responses to, xeno-
botics, although as these observations are examined in
greater depth, it is becoming clear that few, if any, pheno-
typic outcomes will be reliably predicted from genetic anal-
yses at a single locus. True predictive pharmacogenetic
testing relies on having broad individual genotyping capa-
bility and integrated rational therapeutic strategies for dis-
ease, guided by genetic predisposition and risk profiles. The
full potential for predictive pharmacogenetic testing will be
realized only when these goals as well as bioinformatics to
analyze large data sets are also fully developed [Weber and
Cronin, 2000]. Nevertheless, we expect that extension and
refinement of the body of evidence mentioned earlier might
provide a starting point from which to model risk profiles
that will facilitate improvements in drug therapy, in new
drug design, and in other directions of interest. Figure 1
attempts to convey these ideas schematically.
Risk profiles of drug susceptibility would serve as step-
ping stones from the molecular foundations of pharmaco-
genetics to its long-term objectives. Next, we need to ask
what might be some of the obstacles or challenges to ad-
vances in the design and construction of such profiles.
Obviously, the construction of such risk profiles necessi-
tates the collection of genomic data on a large scale. Al-
though the number of pharmacogenetic traits that have been
Fig. 1. Pharmacogenetics in the year 2000.
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extensively characterized as of this writing probably con-
siderably exceeds the estimate of a hundred traits made
about 10 years ago, molecular studies indicate that such
traits are usually associated with only a limited number of
important variants. This raises the prospect that these genes
and related haplotypes may be cataloged relatively quickly
for many populations of interest. As the first stage of the
Human Genome Project nears completion [Watson, 2000],
the problem of collecting information on human pharmaco-
genetic diversity may presently be solved.
Additionally, for drug susceptibility profiling, we need to
know the functional consequences of the human pharmaco-
genetic diversity. This means that the relationship of an
individual’s genotype (or haplotype) to his/her expressed
phenotype must be determined. Pharmacologists usually
think of an altered drug response as a consequence of a
peculiarity in either the pharmacokinetics or the pharmaco-
dynamics of the drug. Usually one suspects a defect in
mechanisms that control the drug level (absorption, distri-
bution, elimination) or of the receptor that mediates the
response to the drug [see Weber, 1997, Chapter 2]. Al-
though a defective pharmacokinetic mechanism is relatively
easily identified, our present understanding of altered path-
ways or mechanisms at the molecular level that contribute
to the pharmacodynamic (receptor-mediated) diversity of
drug responses is relatively rudimentary. Thus, establishing
genotype–phenotype relationships, particularly for the re-
sponses attributable to pharmacodynamic diversity, repre-
sents a major challenge, and one that is likely to require
more than technical development for resolution.
However, even when the relationship of genotype (or
haplotype) to a drug-susceptible phenotype is reasonably
firm, the clinical application of pharmacogenetic knowledge
to therapeutics is, with few exceptions, as yet unrealized.
There are a number of reasons for limited carryover of this
knowledge to therapeutics, which can best be illustrated by
traits attributable to the human drug-metabolizing enzyme
polymorphisms. These traits have been used to document
the diversity in human drug response in different geographic
and ethnic populations, and to identify the molecular basis
of normal and altered drug responses. They have also shed
light on the mechanisms that explain these responses, and to
define the relationships between genotype and phenotype
that together determine drug susceptibility.
Obviously, these traits have contributed immensely to the
clarification of human variation in response to many drugs,
and are expected to be important in new drug development.
Despite having such an abundant collection of evidence,
carryover to the clinical arena is still limited. Why? One
reason is that much of the evidence collected during the
1960s through the 1980s concerned the polymorphic gene
of interest in isolation from all other genes, and the evidence
obtained was often limited to a few healthy individuals or
small populations. Moreover, many of the earlier studies
were designed to test proof of principle, that is, to test the
relevance of genetic diversity to variation in human drug
response, and were not designed to assess clinical end points
[Weber, 1997].
Several additional limitations are evident from some the
data obtained.
1. There is a lack of clear criteria for assessing the
outcome of the polymorphism.Commonly, we see that
one or more variables (such as genotypes, drug–me-
tabolite ratios, urinary drug/metabolite patterns, or drug
levels) may be used to assess outcome. Often the rela-
tionship between the variables and the clinical implica-
tions of such variation are unclear or incompletely
defined.
2. There is a lack of information about genetic regulation
of P450 drug-metabolizing enzymes by physiological
and pathophysiological factors.Infections or inflam-
matory stimuli, or cytokines and interferons adminis-
tered as therapeutic agents, as well as hormones and
nutritional status can cause changes in the activities or
expression of various forms of cytochrome (CYP450)
enzymes in humans [reviewed in Morgan, 1997; Mor-
gan et al., 1998]. These factors have the potential to
affect, either adversely or favorably, the therapeutic or
toxic effects of drugs. These effects are particularly
crucial for drugs with a low therapeutic index. Al-
though some important findings regarding the effects of
these factors on drug levels of a few drugs have been
known for many years [see Table 1 in Morgan, 1997],
their systematic investigation has begun only recently.
At the present time, very little is known of the effects of
these factors on expression of Phase 1 (CYP450) or the
Phase 2 drug-metabolizing enzyme polymorphisms.
3. There is a lack of adequate large-scale, high-through-
put methodology for metabolic phenotyping.Knowl-
edge of the genotype provides useful information about
drug susceptibility, although this information alone is
usually insufficient to predict the phenotype [Raimundo
et al., 2000 and references therein]. However, genotyp-
ing complemented by phenotyping with probe sub-
strates affords an alternative way of assessing the ac-
tivity of specific drug-metabolizing enzymes in vivo.
For some of the drug-metabolizing enzymes, including
CYP1A2, 2E1, 3A, 2D6, and 2C19, andN-acetyltrans-
ferase (NAT2), the metabolic phenotype can be deter-
mined simultaneously with the aid of a cocktail of
noninteracting substrates [Frye et al., 1997]. These
techniques are employed now mainly in a research
setting. The development of methodology for additional
Phase 1 and Phase 2 enzymes applicable to large-scale,
high-throughput analyses for therapeutic drug monitor-
ing is urgently needed.
4. There is a lack of a clear dose (plasma concentration)–
response relationship for some disorders.For example,
the genetic polymorphism of CYP2D6 has a profound
Effect of Pharmacogenetics on Medicine 183
effect on the pharmacokinetics of antidepressant and
neuroleptic drugs, but there is a paucity of evidence for
relationships between the plasma concentrations of
these agents and their active metabolites and therapeu-
tic response in depression [reviewed in Tucker, 2000].
It has not been possible to demonstrate convincingly
that higher antidepressant drug plasma concentrations
in CYP2D6-poor metabolizers are associated with
greater amelioration of depression. The disconnection
between the diagnosis, or severity, of depression and its
pharmacokinetics, which is yet to be explained, pre-
sents an obstacle to the management of this disorder.
Nowadays, pharmacogenetics, or pharmacogenomics, is
a hot topic at national and international scientific confer-
ences. Recently, the Human Genome Project has received a
great deal of attention at such conferences and in the pop-
ular press. The idea that genes contribute to drug response,
and that drugs may be tailored to fit the genes of patients has
also been treated informatively in the press [Altman, 1998;
Carr, 1998; Wade, 1999, 2000; Lemonick, 2000]. Yet the
belief that the effects of drugs on individuals are attributed
primarily to the drug administered, and that the drug recip-
ient is merely a passive bystander to these events, is much
more widely held. People perceive an influence of heredity
on health and disease, especially with respect to its effect on
the occurrence of physical and mental traits in members of
their families, but may be unaware of the harmful effects of
medical drugs on genetically susceptible persons. It appears
that we still have far to go in getting these points across to
the general public and to explain the promise of pharmaco-
genetics to better medical care. Whether physicians and
pharmacists in mainstream practice are sufficiently prepared
to extend the benefits of individualized medicine to their
patients raises another question. It is probably unrealistic to
assume that the majority of these practitioners will respond
effectively to such information without additional training
and assistance.
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